BR132018069012E2 - use of human polyclonal antibodies or fragments thereof, and pharmaceutical composition - Google Patents

use of human polyclonal antibodies or fragments thereof, and pharmaceutical composition Download PDF

Info

Publication number
BR132018069012E2
BR132018069012E2 BR132018069012A BR132018069012A BR132018069012E2 BR 132018069012 E2 BR132018069012 E2 BR 132018069012E2 BR 132018069012 A BR132018069012 A BR 132018069012A BR 132018069012 A BR132018069012 A BR 132018069012A BR 132018069012 E2 BR132018069012 E2 BR 132018069012E2
Authority
BR
Brazil
Prior art keywords
fragments
pharmaceutical composition
polyclonal antibodies
human polyclonal
fetus
Prior art date
Application number
BR132018069012A
Other languages
Portuguese (pt)
Inventor
Schenker Eran
Sagiv Yuval
Original Assignee
Kamada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kamada Ltd filed Critical Kamada Ltd
Publication of BR132018069012E2 publication Critical patent/BR132018069012E2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

uso de anticorpos policlonais humanos ou fragmentos destes, e, composição farmacêutica são providos métodos para prevenção ou tratamento de uma infecção causada por um vírus do gênero flavivirus , e em particular pela doença do zika vírus, em um feto de mamífero. um exemplo para tal tratamento é uma imunização passive do feto por um anticorpo, e em particular, um anticorpo policlonal ou fragmento deste.use of human polyclonal antibodies or fragments thereof, and pharmaceutical composition, methods are provided for preventing or treating an infection caused by a virus of the genus flavivirus, and in particular by Zika virus disease, in a mammal fetus. an example for such treatment is a passive immunization of the fetus by an antibody, and in particular, a polyclonal antibody or fragment thereof.

BR132018069012A 2016-03-03 2018-09-19 use of human polyclonal antibodies or fragments thereof, and pharmaceutical composition BR132018069012E2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662302842P 2016-03-03 2016-03-03

Publications (1)

Publication Number Publication Date
BR132018069012E2 true BR132018069012E2 (en) 2020-04-07

Family

ID=59743561

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112018067353A BR112018067353A2 (en) 2016-03-03 2017-02-27 pharmaceutical composition and use of an active compound to treat a disease caused by flavivirus viruses in a mammalian fetus
BR132018069012A BR132018069012E2 (en) 2016-03-03 2018-09-19 use of human polyclonal antibodies or fragments thereof, and pharmaceutical composition

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112018067353A BR112018067353A2 (en) 2016-03-03 2017-02-27 pharmaceutical composition and use of an active compound to treat a disease caused by flavivirus viruses in a mammalian fetus

Country Status (3)

Country Link
BR (2) BR112018067353A2 (en)
IL (1) IL261536B (en)
WO (1) WO2017149528A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113372441B (en) * 2018-04-04 2023-03-10 中国科学院微生物研究所 High-sensitivity yellow fever virus humanized monoclonal antibody and application thereof
CA3104603A1 (en) * 2018-06-21 2019-12-26 Emergent Biosolutions Canada Inc. Zika neutralizing antibody compositions and methods of using the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877187B2 (en) * 2005-07-25 2014-11-04 Avianax, Llc Therapeutic antibodies for treatment and prophylaxis of transmittable viral diseases

Also Published As

Publication number Publication date
IL261536B (en) 2022-07-01
IL261536A (en) 2018-10-31
WO2017149528A1 (en) 2017-09-08
BR112018067353A2 (en) 2019-01-15

Similar Documents

Publication Publication Date Title
CL2022003763A1 (en) Human antibodies against Ebola virus glycoprotein
MX2021007679A (en) Human antibodies to influenza hemagglutinin.
UY37336A (en) ANTI-VIRUS ANTIBODIES OF ZIKA AND METHODS OF USE
BR112016028066A2 (en) vaccine composition; idessuis; ridessuis; antibody; parenteral composition; use of an idessuis or ridessuis protein; and host cell
CL2017000335A1 (en) Joint treatments with anti cd40 antibodies
ES2692773T3 (en) Treatments for fibrosis
CL2017002686A1 (en) Methods to treat or prevent migraine headache
BR112016025009A2 (en) Human Antibodies to Middle East Respiratory Syndrome - Surface Protein
UA118453C2 (en) Modulation of tumor immunity
MX2016012124A (en) Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof.
CO2021004456A2 (en) Multivalent pneumococcal vaccines
BR112018070302A2 (en) agents that recognize the clever-1 epitope and their uses
BR112020015498A8 (en) ANTI-PD-1 ANTIBODIES
BR112016018082A2 (en) antibodies useful in passive immunization of influenza and compositions, combinations and methods for their use.
WO2015112836A3 (en) Antibodies against f glycoprotein of hendra and nipah viruses
UY36820A (en) SPECIFIC MONOCLONAL ANTIBODIES FOR ANTIGEN P OF HUMAN SYNCHRIRY RESPIRATORY VIRUS (VRSH), PRODUCED AND SECRETED BY CELLULAR HYBRIDIDES, USEFUL FOR DETECTION AND DIAGNOSIS OF INFECTION CAUSED BY VRS
AR100944A1 (en) INTERFERON ANTAGONIST ANTIBODIES a Y w
WO2016011035A8 (en) Neutralizing anti-influenza b antibodies and uses thereof
BR132018069012E2 (en) use of human polyclonal antibodies or fragments thereof, and pharmaceutical composition
BR112019011350A2 (en) combination therapy
BR112016015078A2 (en) method for preventing or treating h7n9 influenza virus infection, antibody use and pharmaceutical composition
CL2020001884A1 (en) Human Antibodies to Influenza Hemagglutinin.
PH12017501943A1 (en) Influenza virus neutralizing peptidomimetic compounds
BR112017019816A2 (en) compounds, pharmaceutical composition, method for the prophylactic or therapeutic treatment of kidney and / or liver disease in a subject, and use of a compound
CL2016000915A1 (en) Use of a composition comprising at least one humanized monoclonal antibody or neutralizing molecules that neutralize the function of the tslp and / or tslpr and / or ox40l and / or cd177 molecules, to prepare a medicament for the treatment or to lessen the symptoms and disease of patients infected with human metapneumovirus (hmpv)

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]